Complete Story
05/24/2017
NCCN has published updates to the NCCN Guidelines® and the NCCN Compendium® for Bladder Cancer.
NCCN has published updates to the NCCN Guidelines® and the NCCN Compendium® for Bladder Cancer. These NCCN Guidelines® are currently available as Version 4.2017.
- Principles of Systemic Therapy (BL-G 2 of 4)
- Subsequent systemic therapy for locally advanced or metastatic disease
- “Avelumab” was added as a standard regimen option with a category 2A designation for:
- Bladder cancer
- Upper GU tract tumors: Renal pelvis
- Upper GU tract tumors: Urothelial carcinoma of the ureter
- Urothelial carcinoma of the prostate
- Primary carcinoma of the urethra (urothelial carcinomas only).
- The Discussion section has been updated to reflect the changes in the algorithm. (MS-1)
- Subsequent systemic therapy for locally advanced or metastatic disease
*For your reference, the previous update (Version 3.2017) to the NCCN Guidelines for Bladder Cancer, published on May 8, 2017, is available at the following link: https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf
For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Drugs & Biologics Compendium (NCCN Compendium®), the NCCN Biomarkers Compendium®, the NCCN Chemotherapy Order Templates (NCCN Templates®), the NCCN Radiation Therapy Compendium™, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.
Report Broken Links
Have you encountered a problem with a URL (link) on this page not working or displaying an error message? Help us fix it!